Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
FibroBiologics, Inc. - Common Stock
(NQ:
FBLG
)
1.459
-0.091 (-5.86%)
Streaming Delayed Price
Updated: 12:26 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about FibroBiologics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Granted Extension by Nasdaq to Regain Compliance
February 23, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
Get insights into the top gainers and losers of Wednesday's after-hours session.
↗
February 18, 2026
Via
Chartmill
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
February 10, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
February 05, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the DealFlow Discovery Conference
January 20, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics CEO Issues Letter to Shareholders
January 07, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
January 06, 2026
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
January 05, 2026
FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatments
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
December 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
December 15, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Which stocks are gapping on Monday?
↗
December 15, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Monday's pre-market session: top gainers and losers
↗
December 15, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
December 10, 2025
Platform Poised to Expand into Joint and Cartilage Repair
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Payoff of Outstanding Debt
November 26, 2025
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 25, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Which stocks are experiencing notable movement on Monday?
↗
November 24, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Top movers in Monday's session
↗
November 24, 2025
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
The market is filled with gapping stocks in Monday's session.
↗
November 24, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
November 20, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 19, 2025
Via
Benzinga
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 06, 2025
Via
Benzinga
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at Bio-Europe 2025
October 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
